

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ketavet Veterinary

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Ketamine:	100 mg
(Equivalent to ketamine hydrochloride)	115.36 mg

Excipient(s):

Benzethonium chloride:	0.10 mg
------------------------	---------

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection.

Clear, colourless solution, free from visible evidence of contamination.

4. CLINICAL PARTICULARS

4.1 Target species

Dogs, cats

4.2 Indications for use, specifying the target species

The product may be used to induce anaesthesia:

- a) in conjunction with butorphanol and medetomidine in the dog and the cat.
- b) in conjunction with xylazine in the dog and the cat. Based on the benefit/risk assessment performed by the veterinarian the product may be used as a sole agent for restraint and minor surgical procedures where muscle relaxation is not required in the domestic cat.

4.3 Contraindications

Do not use in animals with pre-existing hepatic or renal pathology.

Do not use in animals with severe cardiac de-compensation, or with apparent high blood pressure or glaucoma.

Do not reverse ketamine combinations in dogs with atipamezole.

Do not use ketamine as a sole agent in dogs.

Do not use in animals with eclampsia or pre-eclampsia.

Do not use for surgical intervention on pharynx, larynx, trachea or bronchial tree, if sufficient relaxation is not ensured by administration of a muscle relaxant (intubation obligatory).

Do not use in cases of known hypersensitivity to the active substance or any of the excipients.

4.4 Special warnings for each target species

For very painful and major surgical interventions, as well as for maintenance of anaesthesia, a combination with injectable or inhalation anaesthetics is necessary. For surgical and diagnostic procedures requiring muscle relaxation, the concomitant use of muscle-relaxants is necessary.

For improvement of anaesthesia or prolongation of effect, ketamine can be combined with α_2 -receptor agonists, anaesthetics, neuroleptanalgesics, tranquilizers and inhalational anaesthetic agents.

4.5 Special precautions for use

Special precautions for use in animals

It is generally accepted as good anaesthetic practice to fast animals for a period prior to anaesthesia where possible.

Induction and recovery should be allowed to occur in quiet and calm surroundings.

A small proportion of animals have been reported to be unresponsive to ketamine as an anaesthetic agent at normal dosages.

Use of premedicants should be followed by a suitable reduction in dosage.

Atropine premedication may reduce salivation in cats. Since use of atropine with α_2 -agonists, which are often administered with ketamine, may increase arterial blood pressure, heart rate and the incidence of arrhythmias, atropine premedication should only be used according to a benefit-risk assessment by the responsible veterinarian.

Muscular twitching and tonic convulsions have been reported in the cat at recommended dose rates. These subside spontaneously but may be prevented by use of xylazine premedication or controlled by use of ultra-short acting barbiturates in low doses.

In the cat and dog, the eyes remain open and the pupils dilated. The eyes may be protected by covering with a damp gauze swab or using appropriate ointments.

Ketamine may exhibit pro-convulsant and anti-convulsant properties, and therefore should be used with care in patients with seizure disorders.

Ketamine may increase intracranial pressure and therefore, may not be suitable for patients with cerebrovascular insults.

Ketamine should be used with caution when pulmonary disease is present or suspected.

Muscle relaxation is not achieved with ketamine alone.

When used in combination with other products, consult the contraindications and warnings that appear on the relevant data sheets.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

This is a potent drug. Particular care should be taken to avoid accidental self-administration.

Preferably use a guarded needle until the moment of injection.

People with known hypersensitivity to ketamine or to any excipient should avoid contact with the product.

Avoid contact with the skin and eyes. Wash any splashes from skin and eyes immediately with large amounts of water.

In case of accidental self-injection, or if symptoms occur after ocular/oral contact, seek medical advice immediately and show the package leaflet or the label to the physician, but DO NOT DRIVE.

Adverse effects on the foetus cannot be excluded. The veterinary medicinal product should not be administered by pregnant women.

Advice to doctors:

Do not leave patient unattended. Maintain airways and give symptomatic and supportive treatment.

4.6 Adverse reactions (frequency and seriousness)

Some pain after intramuscular injection may be observed very rarely.

Salivation in cats may be observed in very rare cases. Atropine premedication may reduce this side effect.

Muscular twitching and tonic convulsions have been reported very rarely in cats and dogs at recommended dose rates.

In the cat and dog the eyes remain open and the pupils dilated (mydriasis).

Nystagmus may also be observed.

Dose-dependent respiratory depression may occur very rarely. When given too rapidly or in excessive doses, significant respiratory depression may occur.

Increased heart rate and arterial blood pressure have been reported in very rare cases.

Emergence reactions - ataxia, hypersensitivity to stimuli, excitation – may occur very rarely during recovery.

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form

<https://sideeffects.health.gov.il/>.

4.7 Use during pregnancy, lactation or lay

Use of the product has not been assessed during pregnancy and lactation.

Due to transfer of ketamine across the placental barrier, foetal anaesthesia and respiratory depression in neonates may occur.

Use only according to the benefit/risk assessment by the responsible veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

Care should be taken when using ketamine-halothane combinations since the half-life of ketamine is prolonged. Neuroleptanalgesics, tranquilizers, morphine analogues and chloramphenicol potentiate ketamine anaesthesia. Barbiturates and opiates can prolong the recovery period.

4.9 Amounts to be administered and administration route

It should be noted that dosage and routes of administration vary widely between species.

Dogs: intramuscular use,

Cats: intramuscular or intravenous use.

The cap may be safely punctured up to 20 times.

DOG - XYLAZINE/KETAMINE

Dosage and administration: Administer xylazine at a dose rate of 1 mg xylazine/kg by intramuscular injection. Immediately administer the product at a dose rate of 15 mg ketamine/kg (equivalent to 1.5 ml/10 kg bodyweight) by intramuscular injection.

Effect: Dogs become recumbent in approximately 3 minutes and lose their pedal reflex in approximately 7 minutes. Duration of anaesthesia is approximately 24 minutes, the pedal reflex returning about 31 minutes following administration of the product.

Xylazine and Ketamine Canine Anaesthesia – (IM)

Weight of Dog in kg:-	1	3	5	10	15	20	25	30	40
*Xylazine (2% sol.) – ml:-	0.05	0.15	0.25	0.50	0.75	1.00	1.25	1.50	2.00
**Ketamine (100mg/ml) – ml:-	0.15	0.45	0.75	1.50	2.25	3.00	3.75	4.50	6.00

* Based on a dose rate of 1mg xylazine/kg bodyweight

** Based on a dose rate of 15mg ketamine/kg bodyweight

DOG - MEDETOMIDINE/KETAMINE

Dosage and administration: Administer medetomidine at a dose rate of 40 µg medetomidine/kg and the product at a dose rate of 5.0-7.5 mg ketamine/kg bodyweight (equivalent to 0.5-0.75 ml/10 kg), depending on duration of anaesthesia required, by intramuscular injection.

Effect: Loss of pedal reflex occurs approximately 11 minutes following injection at 5 mg/kg and 7 minutes following injection at 7.5 mg/kg. Duration of anaesthesia is approximately 30 and 50 minutes respectively.

Medetomidine and Ketamine Canine Anaesthesia – (IM)

Dosage chart for 5 mg ketamine/kg (duration of anaesthesia approximately 30 minutes)

Weight of Dog in kg:-	1	3	5	10	15	20	25	30	40
*Medetomidine (1 mg/ml) – ml:-	0.04	0.12	0.20	0.40	0.60	0.80	1.00	1.20	1.60
**Ketamine (100 mg/ml) – ml:-	0.05	0.15	0.25	0.50	0.75	1.00	1.25	1.50	2.00

DO NOT REVERSE WITH ATIPAMEZOLE

* Based on a dose rate of 40 µg medetomidine/kg bodyweight

** Based on a dose rate of 5 mg ketamine/kg bodyweight

Medetomidine and Ketamine Canine Anaesthesia – (IM)

Dosage chart for 7.5 mg ketamine/kg (duration of anaesthesia approximately 50 minutes)

Weight of Dog in kg:-	1	3	5	10	15	20	25	30	40
*Medetomidine (1 mg/ml) – ml:-	0.04	0.12	0.20	0.40	0.60	0.80	1.00	1.20	1.60
**Ketamine (100 mg/ml) – ml:-	0.08	0.23	0.38	0.75	1.13	1.50	1.88	2.25	3.00

DO NOT REVERSE WITH ATIPAMEZOLE

* Based on a dose rate of 40 µg medetomidine/kg bodyweight

** Based on a dose rate of 7.5 mg ketamine/kg bodyweight

DOG - BUTORPHANOL/MEDETOMIDINE/KETAMINE

Dosage and administration: Administer butorphanol at a dose rate of 0.1 mg/kg and medetomidine at a dose rate of 25 µg/kg by intramuscular injection. Ketamine injection should be administered 15 minutes following administration of butorphanol and medetomidine at a dose rate of 5 mg ketamine/kg (equivalent to 0.5 ml/10 kg bodyweight) by intramuscular injection.

Effect: Following administration of butorphanol and medetomidine, dogs become recumbent in approximately 6 minutes and lose their pedal reflex in approximately 14 minutes. The pedal reflex returns approximately 53 minutes following administration of ketamine. Sternal recumbency is attained approximately 35 minutes later followed by standing a further 36 minutes later.

Butorphanol, medetomidine, and Ketamine Canine Anaesthesia - (IM)

Weight of Dog in kg:-	1	3	5	10	15	20	25	30	40
*Butorphanol (10 mg/ml) – ml:-	0.01	0.03	0.05	0.10	0.15	0.20	0.25	0.30	0.40
**Medetomidine (1 mg/ml) – ml:-	0.03	0.08	0.13	0.25	0.38	0.50	0.63	0.75	1.00
ADMINISTER BUTORPHANOL AND MEDETOMIDINE BY INTRAMUSCULAR INJECTION AT THE ABOVE DOSE RATES									
WAIT 15 MINUTES BEFORE ADMINISTERING KETAMINE BY IM INJECTION AT THE DOSE RATES BELOW									
***Ketamine (100 mg/ml) - ml	0.05	0.15	0.25	0.50	0.75	1.00	1.25	1.50	2.00
DO NOT REVERSE WITH ATIPAMEZOLE									

* Based on a dose rate of 0.1 mg butorphanol/kg bodyweight

** Based on a dose rate of 25 µg medetomidine/kg bodyweight

*** Based on a dose rate of 5 mg ketamine/kg bodyweight

CAT – KETAMINE AS A SOLE AGENT

Mono-anaesthetic use of ketamine is possible, but to avoid undesired psychomotoric effects combined anaesthesia is recommended.

Dosage and administration: The product on its own may be used by intravenous injection, but intramuscular injection is the recommended route. The dose is 11-33 mg ketamine/kg depending on the degree of restraint or surgical interference that is intended.

Ketamine as a sole agent in cats – (IM, IV)

Weight of Cat in kg:-	1.5	2	2.5	3	3.5	4	4.5	5
MINOR RESTRAINT								
*Ketamine (100 mg/ml) – ml:-	0.16	0.22	0.27	0.33	0.38	0.44	0.49	0.55
MINOR SURGERY								
**Ketamine (100 mg/ml) – ml:-	0.49	0.66	0.82	0.99	1.15	1.32	1.48	1.65

* Based on a dose rate of 11 mg ketamine/kg bodyweight, suitable for minor restraint

** Based on a dose rate of 33 mg ketamine/kg bodyweight, suitable for minor surgery and restraint of fractious cats

Effect: Duration of anaesthesia with the product is 20-40 minutes and recovery takes place over a 1-4 hour period.

For major surgery, ketamine should be used in conjunction with supplemental sedatives or anesthetics. Dosage varies from 1.25-22 mg/kg (0.06-1.1 ml/5 kg) depending on the combination and route of administration used.

Vomiting is unlikely to occur when ketamine is used alone, however, cats should be starved for several hours prior to anaesthesia where possible.

Acepromazine pre-medication with ketamine as a sole agent: Acepromazine can be administered by intramuscular injection, as premedication. Endotracheal intubation can be achieved during ketamine anaesthesia.

Inhalation anaesthesia may be maintained by suitable combinations of methoxyflurane, halothane, nitrous oxide and oxygen.

CAT - XYLAZINE/KETAMINE

Dosage and administration: Administer xylazine at a dose rate of 1.1 mg xylazine/kg (corresponding to 0.28 ml/5 kg bodyweight of xylazine 2% solution). Wait 20 minutes and then administer the product at a dose rate of 22 mg ketamine/kg bodyweight (equivalent to 1.1 ml/5 kg), by intramuscular injection.

Effect: Xylazine may induce vomiting up to 20 minutes after administration. Onset of anaesthesia after intramuscular injection of ketamine takes 3-6 minutes. A xylazine/ketamine combination produces a deeper anaesthesia with more pronounced respiratory and cardiac effects and a longer recovery period than acepromazine/ketamine combinations.

Xylazine and Ketamine Feline Anaesthesia – (IM)

Weight of Cat in kg:-	1.5	2	2.5	3	3.5	4	4.5	5
*Xylazine (2% soln) – ml:-	0.08	0.11	0.14	0.17	0.19	0.22	0.25	0.28
WAIT 20 MINUTES								
**Ketamine (100 mg/ml) – ml:-	0.33	0.44	0.55	0.66	0.77	0.88	0.99	1.10

* Based on a dose rate of 1.1 mg xylazine/kg bodyweight

**Based on a dose rate of 22 mg ketamine/kg bodyweight

CAT - MEDETOMIDINE/KETAMINE

Dosage and administration:

a) Intramuscular

Administer medetomidine at a dose rate of 80 µg medetomidine/kg by intramuscular injection. This should be followed immediately by the intramuscular injection of the product at a dose rate of 2.5 mg up to a maximum of 7.5 mg ketamine/kg bodyweight (equivalent to 0.12-0.38 ml/5 kg).

Medetomidine and Ketamine Feline Anaesthesia – (IM)

Weight of Cat in kg:-	1.5	2	2.5	3	3.5	4	4.5	5
*Medetomidine (1 mg/ml) – ml:-	0.12	0.16	0.20	0.24	0.28	0.32	0.36	0.40
**Ketamine (100 mg/ml) – ml:-	0.08	0.10	0.13	0.15	0.18	0.20	0.23	0.25

* Based on a dose rate of 80 µg medetomidine/kg bodyweight

** Based on a dose rate of 5 mg ketamine/kg bodyweight

b) Intravenous

Medetomidine and the product may be also administered by intravenous injection at the following dose rates: 40 µg medetomidine/kg and 1.25 mg ketamine/kg.

Medetomidine and Ketamine Feline Anaesthesia – (IV)

Weight of Cat in kg:-	1.5	2	2.5	3	3.5	4	4.5	5
* Medetomidine (1 mg/ml) – ml:-	0.06	0.08	0.10	0.12	0.14	0.16	0.18	0.20
**Ketamine (100 mg/ml) – ml:-	0.02	0.03	0.03	0.04	0.05	0.05	0.06	0.06

* Based on a dose rate of 40 µg medetomidine/kg bodyweight

** Based on a dose rate of 1.25 mg ketamine/kg bodyweight

Effects: Onset of anaesthesia is 3-4 minutes (following IM). The duration of surgical anaesthesia varies between 30-60 minutes and is related to the dose of the product used. If required, anaesthesia may be prolonged with halothane and oxygen with or without nitrous oxide.

Atropine is not normally necessary when using a medetomidine/ketamine combination.

Clinical experience has shown that when ketamine and medetomidine have been used intravenously in cats and the need for anaesthesia has passed, administration of 100µg atipamezole/kg by intramuscular injection results in recovery to sternal recumbency in approximately 10 minutes and to standing in approximately 14 minutes.

CAT - BUTORPHANOL/MEDETOMIDINE/KETAMINE

Dosage and administration:

a) Intramuscular

Administer butorphanol at a dose rate of 0.4 mg/kg, medetomidine at a dose rate of 80 µg/kg and the product at a dose rate of 5 mg ketamine/kg bodyweight (equivalent to 0.25 ml/5 kg) by intramuscular injection.

Butorphanol, medetomidine, and Ketamine Feline Anaesthesia - (IM)

Weight of Cat in kg:-	1.5	2	2.5	3	3.5	4	4.5	5
*Butorphanol (10 mg/ml) – ml:-	0.06	0.08	0.10	0.12	0.14	0.16	0.18	0.20
** Medetomidine (1 mg/ml) – ml:-	0.12	0.16	0.20	0.24	0.28	0.32	0.36	0.40
***Ketamine (100 mg/ml) - ml	0.08	0.10	0.13	0.15	0.18	0.20	0.23	0.25

* Based on a dose rate of 0.4 mg butorphanol/kg bodyweight

** Based on a dose rate of 80 µg medetomidine/kg bodyweight

*** Based on a dose rate of 5 mg ketamine/kg bodyweight

b) Intravenous

Administer butorphanol at a dose rate of 0.1mg/kg, medetomidine at a dose rate of 40 µg/kg and the product, depending on depth of anaesthesia required, at a dose

rate of 1.25-2.5mg ketamine/kg bodyweight (equivalent to 0.06- 0.13ml/5kg) by intravenous injection.

Butorphanol, medetomidine, and Ketamine Feline Anaesthesia - (IV)

Dosage chart for 2.5 mg ketamine/kg (duration of anaesthesia approximately 28 minutes).

Weight of Cat in kg:-	1.5	2	2.5	3	3.5	4	4.5	5
*Butorphanol (10 mg/ml) – ml:-	0.02	0.02	0.03	0.03	0.04	0.04	0.05	0.05
** Medetomidine (1 mg/ml) – ml:-	0.06	0.08	0.10	0.12	0.14	0.16	0.18	0.20
***Ketamine (100 mg/ml) – ml:-	0.04	0.05	0.06	0.08	0.09	0.10	0.11	0.13

* Based on a dose rate of 0.1 mg butorphanol/kg bodyweight

** Based on a dose rate of 40µg medetomidine/kg bodyweight

*** Based on a dose rate of 2.5 mg ketamine/kg bodyweight

Effects: Cats become recumbent in 2-3 minutes following intramuscular injection. Loss of pedal reflex occurs 3 minutes post-injection. At 45 minutes post-induction, reversal with 200 µg atipamezole/kg results in return of pedal reflex 2 minutes later, sternal recumbency 6 minutes later and standing 31 minutes later. The approximate time scales following intravenous administration are provided in the following table.

Approximate time scales when using the triple combination intravenously

The Product* Dose mg/kg	Time to recumbency	Time to loss of pedal reflex	Time to return of pedal reflex	Time to sternal recumbency	Time to standing
1.25	32 secs	62 secs	26 mins	54 mins	74 mins
2.50	22 secs	39 secs	28 mins	62 mins	83mins

* In conjunction with butorphanol at 0.1 mg/kg and medetomidine at 40 µg/kg

Clinical experience has shown that reversal, at any stage, with 100 µg atipamezole/kg results in return of the pedal reflex 4 minutes later, sternal recumbency 7 minutes later and standing 18 minutes later.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Overdose of ketamine may result in CNS effects (e.g., seizures), apnoea, arrhythmia and dysphagia.

Respiratory depression may occur following administration of high doses of ketamine. If necessary, suitable artificial aids to maintain ventilation and cardiac output should be used until sufficient detoxification has taken place to enable a return to adequate spontaneous ventilation and cardiac activity. Pharmacological cardiac stimulants are not recommended, unless no other supportive measures are available.

4.11 Withdrawal period(s)

Not applicable

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group:

Nervous system; anaesthetics, general; other general anaesthetics; ketamine

ATCVet Code. QN01AX03

5.1. Pharmacodynamic properties

The product is a dissociative anaesthetic agent for use by intramuscular or intravenous injection.

The product induces a state of catalepsy with amnesia and analgesia; muscle tone is maintained including the pharyngeal and laryngeal reflexes. The heart rate, blood pressure and cardiac output are increased; respiratory depression is not a noticeable feature. All these characteristics may be modified if the product is used in combination with other agents.

5.2. Pharmacokinetic Particulars

Ketamine is distributed to all body tissues rapidly after intravenous administration, with the highest levels found in the brain, liver, lung and fat. Plasma protein binding is approximately 53% in the dog and 37-53% in the cat. In most species, ketamine is metabolised in the liver and these metabolites, along with unmetabolised ketamine, are eliminated in urine. In cats, ketamine is almost exclusively excreted unchanged in the urine. The elimination half-life in the cat has been reported to be approximately 1 hour. The redistribution of ketamine out of the CNS is more of a factor in determining duration of anaesthesia than the elimination half-life.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Benzethonium chloride

Water for injections

6.2 Major Incompatibilities

Due to a chemical incompatibility, do not mix barbiturates or diazepam with ketamine in the same syringe.

Do not mix with any other veterinary medicinal product.

6.3 Shelf life

Do not use the veterinary medicinal product after the expiry date (exp. date) mentioned on the package. The expiry date refers to the last day of that month. Shelf life after first opening the immediate packaging: 28 days. Discard unused material.

6.4. Special precautions for storage

Store below 25°C. Store in the original container in order to protect from light. Prevent poisoning! To prevent poisoning, keep this medicine and all other medicines, in a closed place, out of the reach and sight of children and/or infants.

6.5 Nature and composition of immediate packaging

Clear colourless 10 ml or 50 ml type I glass vials with chlorobutyl rubber stoppers
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Zoetis Israel Holding B.V., 5 Atir Yeda Street, Kfar Saba, Israel

8. MARKETING AUTHORISATION NUMBER

159-57-34658-00

9. MANUFACTURER

Zoetis Manufacturing & Research Spain, S.L.,
Ctra. Camprodon "La Riba", Vall de Bianya, Girona, Spain

10. DATE OF REVISION OF THE TEXT

Revised in September 2022 according to MOHs guidelines